Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
Stocks in this Quantisnow insightHealth Care
Historical context for INTS
Across the 7 sessions after earlier INTS headlines, the stock closed higher 4 times and lower 3 times, with a median move of 10.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | INTS | SPY |
|---|---|---|---|
| Feb 13, 2026 | Intensity Therapeutics Announces Reverse Stock Split | -32.6% | +0.1% |
| Jan 13, 2026 | Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities | +1.4% | -0.2% |
| Dec 11, 2025 | Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium | +7.3% | +0.2% |
| Dec 5, 2025 | Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement | +10.8% | +0.2% |
| Dec 4, 2025 | Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium | +12.3% | +0.1% |
| Nov 7, 2025 | Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | -6.2% | +0.1% |
Quantisnow market dataNASDAQ
INTS
Intensity Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2023
Get push alerts for INTS
Full INTS profile on Quantisnow Follow INTS and get a push notification the moment its next story breaks.